Superhumps in Cataclysmic Binaries. XXV. q_crit, epsilon(q), and Mass-Radius

We report on successes and failures in searching for positive superhumps in cataclysmic variables, and show the superhumping fraction as a function of orbital period. Basically, all short-period systems do, all long-period systems don't, and a 50% success rate is found at P_orb=3.1+-0.2 hr. We can use this to measure the critical mass ratio for the creation of superhumps. With a mass-radius relation appropriate for cataclysmic variables, and an assumed mean white-dwarf mass of 0.75 M_sol, we find a mass ratio q_crit=0.35+-0.02. We also report superhump studies of several stars of independently known mass ratio: OU Virginis, XZ Eridani, UU Aquarii, and KV UMa (= XTE J1118+480). The latter two are of special interest, because they represent the most extreme mass ratios for which accurate superhump measurements have been made. We use these to improve the epsilon(q) calibration, by which we can infer the elusive q from the easy-to-measure epsilon (the fractional period excess of P_superhump over P_orb). This relation allows mass and radius estimates for the secondary star in any CV showing superhumps. The consequent mass-radius law shows an apparent discontinuity in radius near 0.2 M_sol, as predicted by the disrupted magnetic braking model for the 2.1-2.7 hour period gap. This is effectively the "empirical main sequence" for CV secondaries.Comment: PDF, 45 pages, 9 tables, 12 figures; accepted, in press, to appear November 2005, PASP; more info at http://cba.phys.columbia.edu

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia:The HypoDeg randomized, controlled, open-label, crossover trial

AIM: To investigate whether the long‐acting insulin analogue insulin degludec compared with insulin glargine U100 reduces the risk of nocturnal symptomatic hypoglycaemia in patients with type 1 diabetes (T1D). METHODS: Adults with T1D and at least one episode of nocturnal severe hypoglycaemia during the last 2 years were included in a 2‐year prospective, randomized, open, multicentre, crossover trial. A total of 149 patients were randomized 1:1 to basal‐bolus therapy with insulin degludec and insulin aspart or insulin glargine U100 and insulin aspart. Each treatment period lasted 1 year and consisted of 3 months of run‐in or crossover followed by 9 months of maintenance. The primary endpoint was the number of blindly adjudicated nocturnal symptomatic hypoglycaemic episodes. Secondary endpoints included the occurrence of severe hypoglycaemia. We analysed all endpoints by intention‐to‐treat. RESULTS: Treatment with insulin degludec resulted in a 28% (95% CI: 9%‐43%; P = .02) relative rate reduction (RRR) of nocturnal symptomatic hypoglycaemia at level 1 (≤3.9 mmol/L), a 37% (95% CI: 16%‐53%; P = .002) RRR at level 2 (≤3.0 mmol/L), and a 35% (95% CI: 1%‐58%; P = .04) RRR in all‐day severe hypoglycaemia compared with insulin glargine U100. CONCLUSIONS: Patients with T1D prone to nocturnal severe hypoglycaemia have lower rates of nocturnal symptomatic hypoglycaemia and all‐day severe hypoglycaemia with insulin degludec compared with insulin glargine U100

Superhumps in Cataclysmic Binaries. XXIV. Twenty More Dwarf Novae

We report precise measures of the orbital and superhump period in twenty more dwarf novae. For ten stars, we report new and confirmed spectroscopic periods - signifying the orbital period P_o - as well as the superhump period P_sh. These are GX Cas, HO Del, HS Vir, BC UMa, RZ Leo, KV Dra, KS UMa, TU Crt, QW Ser, and RZ Sge. For the remaining ten, we report a medley of P_o and P_sh measurements from photometry; most are new, with some confirmations of previous values. These are KV And, LL And, WX Cet, MM Hya, AO Oct, V2051 Oph, NY Ser, KK Tel, HV Vir, and RX J1155.4-5641. Periods, as usual, can be measured to high accuracy, and these are of special interest since they carry dynamical information about the binary. We still have not quite learned how to read the music, but a few things are clear. The fractional superhump excess epsilon [=(P_sh-P_o)/P_o] varies smoothly with P_o. The scatter of the points about that smooth curve is quite low, and can be used to limit the intrinsic scatter in M_1, the white dwarf mass, and the mass-radius relation of the secondary. The dispersion in M_1 does not exceed 24%, and the secondary-star radii scatter by no more than 11% from a fixed mass-radius relation. For the well-behaved part of epsilon(P_o) space, we estimate from superhump theory that the secondaries are 18+-6% larger than theoretical ZAMS stars. This affects some other testable predictions about the secondaries: at a fixed P_o, it suggests that the secondaries are (compared with ZAMS predictions) 40+-14% less massive, 12+-4% smaller, 19+-6% cooler, and less luminous by a factor 2.5(7). The presence of a well-defined mass-radius relation, reflected in a well-defined epsilon(P_o) relation, strongly limits effects of nuclear evolution in the secondaries.Comment: PDF, 62 pages, 7 tables, 21 figures; accepted, in press, to appear November 2003, PASP; more info at http://cba.phys.columbia.edu

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely